Trials / Recruiting
RecruitingNCT05617859
Lenvatinib for Advanced Bone and Soft Tissue Sarcoma
A Multicenter, Open, One-arm Phase II Study of Ranvastinib Mesylate Capsules in the Treatment of Advanced Bone and Soft Tissue Sarcoma After Chemotherapy Failure
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- Henan Cancer Hospital · Other Government
- Sex
- All
- Age
- 10 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
A total of 60 patients with metastatic/surgically unresectable bone and soft tissue sarcomas who had previously received multi-target TKI therapy and failed were enrolled to evaluate the efficacy and safety.
Detailed description
To evaluate the efficacy and safety of lenvatinib mesylate capsule in patients with metastatic/surgically unresectable bone and soft tissue sarcomas who had previously received multitarget TKI therapy and failed.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lenvatinib mesylate capsule | Lenvatinib mesylate capsule, 8mg (body weight ≤60kg) or 12mg (body weight \>60kg), orally, once daily. Take the medicine about half an hour after meals (the time of taking the medicine should be the same as possible every day) and take it with warm water. |
Timeline
- Start date
- 2023-04-30
- Primary completion
- 2026-12-31
- Completion
- 2026-12-31
- First posted
- 2022-11-16
- Last updated
- 2023-08-21
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05617859. Inclusion in this directory is not an endorsement.